GLADIATOR Ulcerative Colitis (UC) Study

More information
Starting date: 
April, 2021

Are you suffering from Ulcerative Colitis (UC)?

The GLADIATOR UC Team is looking for people with moderately active UC to join a clinical research study assessing an investigational drug.

Reasons to participate:

✔ Opportunity to be a part of a clinical study for moderately active UC

✔ Potentially get access to the oral, once-daily, investigational drug at no cost

✔ Be monitored by gastrointestinal (GI) specialists

✔ You may be eligible to join an extension study and receive the investigational drug


Is the GLADIATOR UC Study Right for You?

The answer may be yes, if you:

✔ Are 18 to 80 years of age

✔ Have been diagnosed with moderately active UC ≥ 3 months prior to screening

✔ Did not respond to, are no longer responding to, or did not tolerate another UC therapy

 *There are other eligibility criteria too. Contact the study sites to learn more.


What else do I need to know? If you are eligible and decide to participate:

You’ll get complete information: The study team will explain the possible benefits and risks of the study.

Care and medication provided: All investigational treatment and study-related care will be provided to you at no cost.

Investigational drug vs placebo – You will have a 2-in-3 chance of receiving the investigational drug and a 1-in-3 chance of receiving the placebo. Placebo looks like the investigational drug, but contains no actual medicine.

There is no obligation and participation in this study is voluntary.


Participating countries in Europe:

Belgium, Czech Rep., France, Germany, Israel, Italy, Portugal, Spain

For more information on the countries and participating sites please see below. More site contact details may become available so please check back. 




(31002) – AZ Delta, Roeselare

Investigator: Dr. Filip Baert (, +3251237215)

Study Coordinator: Lien Decaesteker (, +3251237512)

(31009) - AZ Sint-Lucas, Gent

Investigator: Dr. Harald Peeters (, 0032 (0)9 224 64 80)

Study Coordinator: Sophie Claeys (, 0032 (0)9 224 51 70)


Czech Republic


(34004) - ISCARE a.s., Prague, Praha 9, 190 00

(34005) - Hepato-Gastroenterologie HK s.r.o., Hradec, Kralov, 500 12

(34009) - Nemocnice Slany, Slany, 274 01

(34010) - Fakultni nemocnice Ostrava, Ostrava

Investigator: Dr. Pavel Svoboda (

(34014) - PreventaMed  s.r.o., Olomouc

Investigator: Dana Mohrova (, 420-6044-99100)



It is important to discuss this possibility with your general practitioner/family doctor


(35004) - CHU Rennes - Hôpital Pontchaillou , Rennes
Investigator: Dr. Guillaume Bouguen (, 0299289972)
Study Coordinator: Cèline Gautier (, 0299289889 poste 85809)

(35007) - CHU de Grenoble - Hôpital Nord, Grenoble

(35008) - CHU Nice - Hôpital de l'Archet 2 - URC Gastro-ènterologie, Nice
Investigator: Dr. Xavier Hebuterne (

(35009) - CHU Clermont Ferrand - Hôpital d'Estaing, Clermont-Ferrand Cedex 1

(35010) - Centre Hospitalier Universitaire de Nantes - Hotel-Dieu, Nantes Cedex 1, France, 44093

*It is important to discuss this possibility with your general practitioner/family doctor




(36001) - Charité - Campus Charité Mitte, Berlin

(36004) - Magen-Darm-Zentrum Remscheid, Remscheid

(36008) - Universitaetsklinikum Schleswig-Holstein - Campus Kiel

(36011) - Schwerpunktpraxis Bonn, Bonn

(36014) - Florence-Nightingale-Krankenhaus-Diakonie Kaiserswerth, Düsseldorf

(36015) - Johanna-Etienne-Krankenhaus, Neuss




(39001) - Rabin Medical Center-Beilinson Campus, Petach Tikva

(39003) - Kaplan Medical Center, Rehovot

Investigator: Dr. Bruce N. Mosenkis (, 972-8-9441587)

Study Coordinator: Meirav Karny (, 972-8-9441587)

(39005) - Galilee Medical Center, Nahariya

(39006) - Shaare Zedek Medical Center, Jerusalem

(39008) - Wolfson Medical Center, Holon





(56006) - Centro Hospitalar Universitario de Sao Joao, E.P.E., Porto




(47003) - Hospital General Universitario de Alicante, Alicante, 28046

(47005) - Hospital Universitario La Paz, Madrid